Patents by Inventor Patrick A. Singleton

Patrick A. Singleton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF OPIOID ANTAGONISTS
    Publication number: 20210145825
    Abstract: Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Application
    Filed: October 19, 2020
    Publication date: May 20, 2021
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G.N. Garcia
  • Treatment with opioid antagonists and mTOR inhibitors
    Patent number: 10383869
    Abstract: Embodiments of the invention provide methods of treating a disorder or disease characterized by cellular proliferation and migration by co-administering a synergistically effective amount of an mTOR inhibitor and a ?-opioid receptor antagonist.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: August 20, 2019
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Jonathan Moss, Patrick A. Singleton
  • USE OF OPIOID ANTAGONISTS
    Publication number: 20180008594
    Abstract: Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Application
    Filed: July 7, 2017
    Publication date: January 11, 2018
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G.N. Garcia
  • USE OF OPIOID ANTAGONISTS TO ATTENUATE ENDOTHELIAL CELL PROLIFERATION AND MIGRATION
    Publication number: 20170258909
    Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Application
    Filed: May 17, 2017
    Publication date: September 14, 2017
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G.N. Garcia
  • USE OF OPIOID ANTAGONISTS TO ATTENUATE ENDOTHELIAL CELL PROLIFERATION AND MIGRATION
    Publication number: 20170252336
    Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Application
    Filed: May 17, 2017
    Publication date: September 7, 2017
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G.N. Garcia, Chun-Su Yuan
  • Use of opioid antagonists
    Patent number: 9717725
    Abstract: Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: August 1, 2017
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G. N. Garcia
  • Use of opioid antagonists to attenuate endothelial cell proliferation and migration
    Patent number: 9675602
    Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: June 13, 2017
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G. N. Garcia, Chun-Su Yuan
  • Use of opioid antagonists to attenuate endothelial cell proliferation and migration
    Patent number: 9662325
    Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: May 30, 2017
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G. N. Garcia, Chun-Su Yuan
  • Use of opioid antagonists to attenuate endothelial cell proliferation and migration
    Patent number: 9662390
    Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Grant
    Filed: March 7, 2006
    Date of Patent: May 30, 2017
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G. N. Garcia
  • TREATMENT WITH OPIOID ANTAGONISTS AND mTOR INHIBITORS
    Publication number: 20170065581
    Abstract: Embodiments of the invention provide methods of treating a disorder or disease characterized by cellular proliferation and migration by co-administering a synergistically effective amount of an mTOR inhibitor and a ?-opioid receptor antagonist.
    Type: Application
    Filed: November 16, 2016
    Publication date: March 9, 2017
    Inventors: Jonathan Moss, Patrick A. Singleton
  • Treatment with opioid antagonists and mTOR inhibitors
    Patent number: 9526723
    Abstract: Embodiments of the invention provide methods of treating a disorder or disease characterized by cellular proliferation and migration by co-administering a synergistically effective amount of an mTOR inhibitor and a ?-opioid receptor antagonist.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: December 27, 2016
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Jonathan Moss, Patrick A. Singleton
  • USE OF OPIOID ANTAGONISTS TO ATTENUATE ENDOTHELIAL CELL PROLIFERATION AND MIGRATION
    Publication number: 20140323426
    Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Application
    Filed: May 30, 2014
    Publication date: October 30, 2014
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G.N. Garcia, Chun-Su Yuan
  • TREATMENT WITH OPIOID ANTAGONISTS AND MTOR INHIBITORS
    Publication number: 20140163059
    Abstract: Embodiments of the invention provide methods of treating a disorder or disease characterized by cellular proliferation and migration by co-administering a synergistically effective amount of an mTOR inhibitor and a ?-opioid receptor antagonist.
    Type: Application
    Filed: February 12, 2014
    Publication date: June 12, 2014
    Applicant: The University Of Chicago
    Inventors: Jonathan Moss, Patrick A. Singleton
  • MODULATION OF CELL BARRIER DYSFUNCTION
    Publication number: 20140142133
    Abstract: The invention provides prophylactic and therapeutic methods for administering a ?-opioid receptor antagonist, e.g., N-methylnaltrexone or a salt thereof, to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders, e.g., sepsis. Methods of reducing at least a symptom of sepsis and the risk of developing sepsis are also provided.
    Type: Application
    Filed: October 23, 2013
    Publication date: May 22, 2014
    Applicant: The University of Chicago
    Inventors: John C. Alverdy, Jonathan Moss, Mark W. Lingen, Patrick A. Singleton, Joe G.N. Garcia
  • Treatment with opioid antagonists and mTOR inhibitors
    Patent number: 8685995
    Abstract: Embodiments of the invention provide methods of treating a disorder or disease characterized by cellular proliferation and migration by co-administering a synergistically effective amount of an mTOR inhibitor and a ?-opioid receptor antagonist.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: April 1, 2014
    Assignee: The University of Chicago
    Inventors: Jonathan Moss, Patrick A. Singleton
  • USE OF OPIOID ANTAGONISTS TO ATTENUATE ENDOTHELIAL CELL PROLIFERATION AND MIGRATION
    Publication number: 20140066467
    Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Application
    Filed: August 21, 2013
    Publication date: March 6, 2014
    Applicant: The University of Chicago
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G.N. Garcia, Chun-Su Yuan
  • USE OF OPIOID ANTAGONISTS
    Publication number: 20140011831
    Abstract: Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Application
    Filed: August 21, 2013
    Publication date: January 9, 2014
    Applicant: The University of Chicago
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G.N. Garcia
  • Use of opioid antagonists to attenuate endothelial cell proliferation and migration
    Patent number: 8524731
    Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: September 3, 2013
    Assignee: The University of Chicago
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G. N. Garcia, Chun-Su Yuan
  • Use of opioid antagonists
    Patent number: 8518962
    Abstract: Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: August 27, 2013
    Assignee: The University of Chicago
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G. N. Garcia
  • Modulation of Cell Barrier Dysfunction
    Publication number: 20120316190
    Abstract: The invention provides prophylactic and therapeutic methods for administering a ?-opioid receptor antagonist, e.g., N-methylnaltrexone or a salt thereof, to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders, e.g., inflammatory bowel disease. Methods of reducing the symptoms of inflammatory bowel disease and the risk of developing inflammatory bowel disease are also provided.
    Type: Application
    Filed: May 30, 2012
    Publication date: December 13, 2012
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: John C. Alverdy, Jonathan Moss, Mark W. Lingen, Patrick A. Singleton, Joe G.N. Garcia